Delivery Order SPE2DB20D1100-SPE2DB25FD7Y6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $12,445.76 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed-price contract valued at $43,076.07. This non-set-aside competitive award was issued on July 31, 2025, with an ultimate completion date of August 1, 2025. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $31,530.56 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Otezla 30 mg tablets (60-count packages). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 28, 2025. The delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a $13,321.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (60-count packages) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a non-set-aside competitive award issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $7,869.72 delivery order to AmerisourceBergen Drug Corp for 60-count tablets of Otezla 30 mg, a pharmaceutical product for treating autoimmune conditions. This competitive award, issued on July 22, 2025, represents a firm fixed-price contract with a completion date of July 23, 2025, and carries no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its...
- The Defense Logistics Agency awarded a delivery order valued at $5,018.16 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units). This firm fixed-price contract, awarded on July 18, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made through open competition with no set-aside designation, and performance...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,785.70 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) under a firm fixed price contract. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025. This delivery order represents a non-competitive purchase executed under an existing contract vehicle and will be performed at the vendor's location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a $2,500.53 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) on August 4, 2025, with an ultimate completion date of August 5, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The delivery order represents a relatively small-value transaction within AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a delivery order valued at $6,586.94 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) with an ultimate completion date of July 24, 2025. This non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. AmerisourceBergen,...
- The Defense Logistics Agency awarded a delivery order valued at $17,620.78 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a continuation of pharmaceutical supply services under AmerisourceBergen's broader federal contract portfolio. The product will be delivered to the company's corporate...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD7Y6Delivery Order
The Defense Logistics Agency awarded a $34,797 firm fixed price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg, a pharmaceutical product used to treat psoriasis and psoriatic arthritis. The contract was competitively awarded without a set-aside designation and carries an ultimate completion date of August 4, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this delivery order, which represents a child contract under the company's larger federal pharmaceutical procurement vehicle. This delivery order falls under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical supplier to federal military and veteran healthcare systems, routinely fulfilling orders across multiple therapeutic domains including specialty medications, brand-name and generic drugs, and medical supplies. The company's federal contract portfolio demonstrates consistent success in competing for DLA medical supply needs, supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through this comprehensive global pharmaceutical support vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.8k | 8/1/25 |